CGChengxiang Guo

Chengxiang Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chengxiang Guo has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Aijun Qiao

    Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China

    1 shared publication
  • Diru Yao

    Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China

    1 shared publication
  • Ebenezeri Erasto Ngowi

    Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China

    1 shared publication
  • Huan Tu

    College of Computer and Electronic Information, Guangxi University, Nanning 530004, P. R. China

    1 shared publication
  • Liangqing Hu

    College of Computer and Electronic Information, Guangxi University, Nanning, China

    1 shared publication
  • Longlong Wang

    Department of Clinical Medicine of Integrated Traditional Chinese and Western Medicine, The Affiliated International Zhuang Medicine Hospital of Guangxi University of Chinese Medicine, Nanning 530200, China

    1 shared publication

Latest Publications

  • Open Access

    Uncovering Potential Neutrophil-Related Biomarkers for Early AMI Diagnosis

    by Yuwei Liu, Yun Zhang, Lucheng Wang, Diru Yao, Ebenezeri Erasto Ngowi, Moussa Omorou, Ning Hou, Weibo Dai, Longlong Wang, Guihua Yue, et al.

    Early diagnosis of AMI is crucial for improving patient outcomes, yet current clinical tools often lack the requisite sensitivity and specificity for reliable early detection. As neutrophils are the first innate immune responders mobilized following infarction, we employed an integrated multi-omics and machine learning approach to identify neutrophil-driven molecular signatures with diagnostic potential. By analyzing multiple peripheral blood transcriptomic datasets, we conducted differential expression and immune infiltration analyses, followed by machine learning-based feature selection to pinpoint key genes linked to neutrophil activity. Integration of these findings with single-cell transcriptomic data further clarified the neutrophil-specific expression patterns of candidate genes during AMI progression. Using a joint diagnostic model, we identified MCEMP1, NFE2, and AQP9 as the most informative predictors, with MCEMP1 emerging as the primary contributor. Experimental validation in a murine model of myocardial infarction (MI) confirmed rapid upregulation of MCEMP1 after injury, closely mirroring the kinetics of neutrophil infiltration. Collectively, these findings delineate a neutrophil-associated molecular profile of early AMI and highlight MCEMP1 as a promising noninvasive biomarker and a potential therapeutic target for modulating neutrophil-driven myocardial injury.